Published in J Clin Oncol on October 01, 1999
Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res (2008) 1.52
Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer (2005) 1.31
Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res (2009) 1.30
Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer (2003) 1.22
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer (2005) 1.15
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer (2003) 1.13
A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci (2006) 1.09
Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer (2011) 1.06
Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Br J Cancer (2007) 1.05
Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer (2002) 0.99
Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). J Thorac Oncol (2012) 0.93
Current gene expression studies in esophageal carcinoma. Curr Genomics (2009) 0.93
A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma. World J Gastroenterol (2013) 0.91
Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer (2006) 0.89
Feasibility of quality of life assessment in patients with upper gastrointestinal tract cancer. Br J Cancer (2003) 0.89
Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. Strahlenther Onkol (2010) 0.88
Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer. Int J Clin Oncol (2007) 0.87
Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist (2013) 0.87
Advances in targeted therapies and new promising targets in esophageal cancer. Oncotarget (2015) 0.87
Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma. BMC Cancer (2011) 0.86
Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. Invest New Drugs (2004) 0.86
Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept. J Oncol (2009) 0.82
Phase II Trial of Docetaxel and Carboplatin in Patients With Advanced Squamous Carcinoma of the Esophagus (E2298): A Trial of the Eastern Cooperative Oncology Group. Gastrointest Cancer Res (2011) 0.82
Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer. Gastrointest Cancer Res (2011) 0.82
Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol (2009) 0.82
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol (2009) 0.81
A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis (2003) 0.80
Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen. Br J Cancer (2002) 0.79
Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma. World J Gastroenterol (2008) 0.79
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol (2016) 0.78
Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer. Cancer Res Treat (2016) 0.78
Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments. Front Pharmacol (2016) 0.78
Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy. J Gastrointest Oncol (2014) 0.77
New and emerging combination therapies for esophageal cancer. Cancer Manag Res (2013) 0.77
Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Ther Adv Med Oncol (2009) 0.76
Advances in the therapy of gastric cancer. Gastric Cancer (2002) 0.75
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours. Br J Cancer (2003) 0.75
Docetaxel, cisplatin and 5-fluorouracil adjuvant chemotherapy following three-field lymph node dissection for stage II/III N1, 2 esophageal cancer. Mol Clin Oncol (2014) 0.75
Improvement of cisplatin-related renal dysfunction by synthetic ghrelin: a prospective randomised phase II trial. Br J Cancer (2016) 0.75
Nomogram to predict treatment outcome of fluoropyrimidine/platinum-based chemotherapy in metastatic esophageal squamous cell carcinoma. Cancer Res Treat (2013) 0.75
RNA-seq reveals determinants of sensitivity to chemotherapy drugs in esophageal carcinoma cells. Int J Clin Exp Pathol (2014) 0.75
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC Cancer (2016) 0.75
Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. Invest New Drugs (2008) 0.75
Inhibition of pRB Pathway Differentially Modulates Apoptosis in Esophageal Cancer Cells. Transl Oncol (2017) 0.75
A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer. Invest New Drugs (2004) 0.75
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 20.59
Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science (1995) 9.16
Robust perfect adaptation in bacterial chemotaxis through integral feedback control. Proc Natl Acad Sci U S A (2000) 7.67
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med (1999) 7.04
Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth muscle. Science (1989) 5.60
Indium phosphide nanowires as building blocks for nanoscale electronic and optoelectronic devices. Nature (2001) 5.09
Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med (1981) 4.90
A genetic map and recombination parameters of the human malaria parasite Plasmodium falciparum. Science (1999) 4.75
In vivo evidence of structural brain asymmetry in musicians. Science (1995) 4.71
Electrostatic interactions of S4 voltage sensor in Shaker K+ channel. Neuron (1995) 4.49
Adenosine diphosphate as an intracellular regulator of insulin secretion. Science (1996) 4.42
Vitamin D intake and incidence of multiple sclerosis. Neurology (2004) 4.39
Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. J Exp Med (2001) 4.27
Association and stoichiometry of K(ATP) channel subunits. Neuron (1997) 4.21
Separation of human breast cancer cells from blood by differential dielectric affinity. Proc Natl Acad Sci U S A (1995) 4.00
Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci U S A (1985) 3.93
Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab (2001) 3.31
Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int (2016) 3.30
Efficacies of different preparations of glucosamine for the treatment of osteoarthritis: a meta-analysis of randomised, double-blind, placebo-controlled trials. Int J Clin Pract (2013) 3.16
A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med (1998) 3.15
Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum (2004) 3.12
5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer (1999) 3.06
Plasma urate and risk of Parkinson's disease. Am J Epidemiol (2007) 3.06
Automated analysis of protein NMR assignments using methods from artificial intelligence. J Mol Biol (1997) 2.86
A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A (2001) 2.77
Physicochemical foundations and structural design of hydrogels in medicine and biology. Annu Rev Biomed Eng (2000) 2.73
Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res (2000) 2.71
High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis (1996) 2.70
Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc Natl Acad Sci U S A (2001) 2.65
Changes in Friend murine erythroleukaemia cell membranes during induced differentiation determined by electrorotation. Biochim Biophys Acta (1994) 2.65
Structure of a biological oxygen sensor: a new mechanism for heme-driven signal transduction. Proc Natl Acad Sci U S A (1998) 2.62
Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg (2000) 2.60
Peptidase-deficient mutants of Escherichia coli. J Bacteriol (1978) 2.57
Pathway leading to correctly folded beta-tubulin. Cell (1996) 2.55
Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer (1999) 2.49
PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry (1999) 2.48
Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol (1999) 2.48
HIV-1 subtype and second-receptor use. Nature (1996) 2.46
Case study of the effects of atmospheric aerosols and regional haze on agriculture: an opportunity to enhance crop yields in China through emission controls? Proc Natl Acad Sci U S A (1999) 2.44
Proteolytic activation of protein kinase C delta by an ICE/CED 3-like protease induces characteristics of apoptosis. J Exp Med (1996) 2.42
Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene (2010) 2.42
Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst (1999) 2.41
Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry (1989) 2.41
Arterial dilations in response to calcitonin gene-related peptide involve activation of K+ channels. Nature (1990) 2.39
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer (2003) 2.38
Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci U S A (1997) 2.36
Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs (1994) 2.33
FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol (1992) 2.31
Toward understanding the assembly and structure of KATP channels. Physiol Rev (1998) 2.30
Calibration of respiratory inductive plethysmograph during natural breathing. J Appl Physiol (1985) (1989) 2.26
Can selective digestive decontamination avoid the endotoxemia and cytokine activation promoted by cardiopulmonary bypass? Crit Care Med (1993) 2.18
Phosphodiesterase A1, a regulator of cellulose synthesis in Acetobacter xylinum, is a heme-based sensor. Biochemistry (2001) 2.16
A novel RNA-binding motif in influenza A virus non-structural protein 1. Nat Struct Biol (1997) 2.16
Cell separation by dielectrophoretic field-flow-fractionation. Anal Chem (2000) 2.13
Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem (2001) 2.06
A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age. Neuroimage (2004) 2.05
A new focal adhesion protein that interacts with integrin-linked kinase and regulates cell adhesion and spreading. J Cell Biol (2001) 2.04
Theaflavins in black tea and catechins in green tea are equally effective antioxidants. J Nutr (2001) 2.02
p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res (1998) 2.02
Heme-based sensors, exemplified by the kinase FixL, are a new class of heme protein with distinctive ligand binding and autoxidation. Biochemistry (1994) 2.01
Solution structure of the cellular factor BAF responsible for protecting retroviral DNA from autointegration. Nat Struct Biol (1998) 2.00
Inherited cerebellar ataxia in childhood: a pattern-recognition approach using brain MRI. AJNR Am J Neuroradiol (2012) 1.99
Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. J Clin Oncol (1992) 1.98
Basal cortisol levels and cognitive deficits in human aging. J Neurosci (1994) 1.97
Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med (1981) 1.97
Does perchlorate in drinking water affect thyroid function in newborns or school-age children? J Occup Environ Med (2000) 1.96
Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol (1999) 1.92
Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene (2010) 1.91
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer (2011) 1.90
Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res (1990) 1.90
Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proc Natl Acad Sci U S A (1999) 1.89
Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res (1999) 1.88
A precision measurement of the mass of the top quark. Nature (2004) 1.87
Increased corpus callosum size in musicians. Neuropsychologia (1995) 1.85
Cell separation on microfabricated electrodes using dielectrophoretic/gravitational field-flow fractionation. Anal Chem (1999) 1.84
Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol (2001) 1.83
Dos, a heme-binding PAS protein from Escherichia coli, is a direct oxygen sensor. Biochemistry (2000) 1.83
Dielectric properties of human leukocyte subpopulations determined by electrorotation as a cell separation criterion. Biophys J (1999) 1.82
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol (1998) 1.80
Association study of an SNP combination pattern in the dopaminergic pathway in paranoid schizophrenia: a novel strategy for complex disorders. Mol Psychiatry (2004) 1.79
Disease sequence from mutant rhodopsin allele to rod and cone photoreceptor degeneration in man. Proc Natl Acad Sci U S A (1998) 1.75
Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer (2004) 1.75
Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol (1985) 1.72
Differential analysis of human leukocytes by dielectrophoretic field-flow-fractionation. Biophys J (2000) 1.70
Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene (2012) 1.69
effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther (2006) 1.69
Methods for estimation of subsample time delays of digitized echo signals. Ultrason Imaging (1995) 1.69
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol (1998) 1.68
Psychophysical evidence for rod vulnerability in age-related macular degeneration. Invest Ophthalmol Vis Sci (2000) 1.67
SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease. Exp Neurol (2003) 1.66
The LIM family transcription factor Isl-1 requires cAMP response element binding protein to promote somatostatin expression in pancreatic islet cells. Proc Natl Acad Sci U S A (1992) 1.64
Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol (1986) 1.63
Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst (1994) 1.63
Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. Proc Natl Acad Sci U S A (1991) 1.62
An efficient and cost-effective isotope labeling protocol for proteins expressed in Escherichia coli. J Biomol NMR (1998) 1.61
Sex but no hand difference in the isthmus of the corpus callosum. Neurology (1992) 1.60